SR-142,948 je lek koji se koristi u naučnim istraživanjima. On pripada grupi nepeptidnih antagonista selektivnih za neurotenzinske receptore, mada nije selektivan za specifični tip tog receptora.[4] On je korišten u izučavanju uloge neurotenzina u regulaciji aktivnosti dopaminskog receptora[5][6][7][8] i glutamatne signalizacije u mozgu.[9][10] U životinjskim studies SR-142,948 blokira efekte stimulanata,[11] kao što je MDMA.[12]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF (June 2002). „The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area”. Naunyn-Schmiedeberg's Archives of Pharmacology365 (6): 427–33. DOI:10.1007/s00210-002-0574-6. PMID12070755.
↑Panayi F, Colussi-Mas J, Lambás-Señas L, Renaud B, Scarna H, Bérod A (May 2005). „Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization”. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology30 (5): 871–9. DOI:10.1038/sj.npp.1300638. PMID15637639.
↑Reynolds SM, Geisler S, Bérod A, Zahm DS (July 2006). „Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area”. The European Journal of Neuroscience24 (1): 188–96. DOI:10.1111/j.1460-9568.2006.04791.x. PMID16882016.
↑Marie-Claire C, Palminteri S, Romualdi P, Noble F (June 2008). „Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice”. Neuropharmacology54 (7): 1107–11. DOI:10.1016/j.neuropharm.2008.03.001. PMID18410947.